When Su Yi listened to the phone call, when he returned to the dining table, he was not as happy as before.

Seeing this, Shang Shifu took the initiative to ask, "Did you encounter something?"

"It's fine, it's just a little bit of a problem on the company's side, it's no big deal. Su Yi smiled and said.

"What's the problem? You name it, see if we can help. Shang Shifu said.

Su Yi thought for a while, and still said: "Our company is developing a new drug recently, and the effect is not bad at present, so now we are in contact with Haichen Group and want to sell it in their pharmacy, but the conditions of the two sides have not been negotiated, and now we can only find other companies to cooperate." ”

At this time, after Wang Shuo heard these words, he said: "If this is the case, maybe I can help a little, I don't know what kind of new drug your company has launched." ”

"A weight loss drug with traditional Chinese medicine ingredients, the name of the medicine is Xiushen Medicine. Su Yi replied.

"It turns out that the show pill was developed by your company, and now I don't know how popular it is. Shang Shifu was surprised, he had heard of Xiu Shen Yao, but he didn't know that Xiu Shen Yao was a new drug developed by Su Yi Company.

Then, he continued: "If this is the case, Brother Wang really has to help, have you heard of Hua Rentang?"

"I've heard of it. Su Yi said, he couldn't help but be a little puzzled, he didn't know why Shang Shifu suddenly said Huarentang.

"Han Lao, the head of Huarentang, is Brother Wang's father-in-law. Shang Shifu said.

At this time, Wang Shuo spoke again: "Although Huarentang has no way to compare with Haichen Group, it can be regarded as a ranking in China, if you want to cooperate with Huarentang, I can do a little favor and be a middleman." ”

When Su Yi heard this, he couldn't help but be stunned, he didn't know that Wang Shuo and Hua Rentang had such a relationship.

Huarentang is a large-scale listed pharmaceutical company with retail pharmacy chain operation as its core industry, integrating the processing and sales of medicinal materials and the wholesale of Chinese and Western patent medicines. Founded in 1668, it has a history of more than 300 years and is a real century-old brand, of which the Han family holds 65% of the shares.

As the second largest chain pharmacy company in China. Huarentang now has 3,800 chain pharmacies, and also owns 5 hospitals, with an operating income of 182 last year. 600 million yuan, net profit reached 14. 500 million.

This is Su Yi's understanding of Hua Ren Tang, if you only talk about operating income and net profit. This Tongrentang company has far surpassed Haichen Group, but the number of stores is less than that of Haichen Group.

However, in the next five years, Huarentang will open 2,000 new stores, and the number of stores at that time may not be inferior to that of Haichen Group.

"There is Lao Wang Dong to help. Su Yi said.

If Su's Pharmaceutical Company cooperates with Huarentang, it will not be a big deal even if it loses the sales channel of Haichen Group.

"No, it's a mutual benefit for both companies. Wang Shuo said with a smile. He is also optimistic about the market potential of the showman.

Then, he said: "When I go back in the evening, I will go back and say, the problem should not be big, and I will contact your company at that time." ”

"Okay, I'll have someone arrange this too. Su Yi said.

So, in this dinner, Su Yi had an unexpected surprise, which brought a strong partner to Su's Pharmaceutical Company, perhaps after the Xiushen medicine was launched. It is possible to sell directly in retail pharmacies without cooperating with pharmaceutical agents.

In this matter, it can be said that there is no way out of the mountains and rivers, and the willows and flowers are bright and another village.

After dinner in the evening. Su Yi immediately called Liu Yueying, told her the news, and asked her to start preparing to communicate with Hua Ren Tang Group.

On the phone, he could clearly feel Liu Yueying's surprise and strong joy.

……

On March 20, with the help of Wang Shuo. Su's Pharmaceutical Co., Ltd. officially cooperated with Hua Ren Tang Group.

After negotiation between the two parties, the two companies reached a cooperation agreement, under which Su's Pharmaceutical Company intends to sell its drug Xiushen Medicine in Huarentang's directly operated pharmacies and hospitals, directly eliminating the intermediate circulation link and controlling the terminal retail price.

Sushi Pharmaceutical Company and Hua Ren Tang Group reached a consensus that the ex-factory price of Xiu Shen Yao is set at 6 yuan per pill, 120 yuan for a box of 20 pills, and the terminal retail price is 8 yuan per pill, and the retail price of a box is about 160 yuan.

This pricing method is extremely beneficial to Su's Pharmaceutical Company, and its profits are very considerable.

According to the calculation of professionals, as long as the production quantity of Xiushen medicine exceeds a certain quantity, its production cost is not high. Including raw materials, labor, taxes and other costs, the cost of Xiu Shen Yao is 2 yuan a pill, and every time a pill is sold, the profit brought is 4 yuan, and a box of 20 capsules is 80 yuan, which is already counting the total cost of various things.

If the production volume of Xiushen Pharmaceutical is high in the future, the production cost can be further compressed to obtain a higher profit margin.

Compared with other weight loss drugs, the price of Xiu Shen medicine is not high, and the reason why it has such a high profit is because its research and development expenses are extremely low.

Nowadays, it is becoming more and more difficult to develop new drugs, starting from finding new candidate compounds, and then going through layers of trials and approvals, which not only costs a lot of money, but also takes more than ten years, and in the end, these efforts are likely to fail.

According to a recent report published by the Tufts Center for Drug Discovery, the average cost of developing a new drug is $2.6 billion, including $1.4 billion in direct capital investment and $1.2 billion in research and development failures during the same period.

After a new drug is successfully approved for marketing, an average of $300 million will be invested in further research, including the validation of new indications.

As a result, a new drug can cost an average of $2.9 billion over the course of the development process.

Such a high R&D cost, evenly spread over each pill, of course, will make the cost rise many times, if the sales volume is large, it is okay, the cost is not high, if the sales volume is low, the cost is sky-high.

However, the Xiu Shen medicine that Su Yi took out is a very complete and perfect formula, which does not require the R&D team to do another R&D, as long as it directly enters the clinical trial and relevant approvals, and in this process, it saves expensive R&D costs, and the investment is very low, so the cost is naturally not high.

If a pharmaceutical giant wants to develop a similar drug to show off its body, not to mention whether it can do it, even if it succeeds, the R&D cost will not be less than $3 billion, which is the most conservative estimate.

Of course, the cost of this body elixir does not include the spiritual liquid, and for every 20 pills produced, one value of spiritual liquid is required.

There is no way to calculate the actual value of the ichor, and naturally there is no way to include it in the production cost.

However, Su Yi can obtain merit points through guò body medicine, and every time he is taken 20 pills of body medicine, he will feedback 2 merit points back, which is still more cost-effective. (To be continued.) )